On Tuesday, VYNE Therapeutics Inc (NASDAQ: VYNE) was 12.68% up from the session before settling in for the closing price of $0.36. A 52-week range for VYNE has been $0.28 – $4.30.
During the last 5-year period, the sales growth of Healthcare Sector giant was 65.87%. When this article was written, the company’s average yearly earnings per share was at 17.47%. With a float of $22.45 million, this company’s outstanding shares have now reached $25.47 million.
VYNE Therapeutics Inc (VYNE) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward VYNE Therapeutics Inc stocks. The insider ownership of VYNE Therapeutics Inc is 11.86%, while institutional ownership is 27.66%. The most recent insider transaction that took place on Jan 15 ’25, was worth 43,800. In this transaction Director of this company bought 15,000 shares at a rate of $2.92, taking the stock ownership to the 51,472 shares.
VYNE Therapeutics Inc (VYNE) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.29 earnings per share (EPS) during the time that was less than consensus figure (set at -0.23) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.18% during the next five years compared to 65.87% growth over the previous five years of trading.
VYNE Therapeutics Inc (NASDAQ: VYNE) Trading Performance Indicators
You can see what VYNE Therapeutics Inc (VYNE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.90, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.76 in one year’s time.
Technical Analysis of VYNE Therapeutics Inc (VYNE)
Looking closely at VYNE Therapeutics Inc (NASDAQ: VYNE), its last 5-days average volume was 5.3 million, which is a jump from its year-to-date volume of 1.12 million. As of the previous 9 days, the stock’s Stochastic %D was 85.79%.
During the past 100 days, VYNE Therapeutics Inc’s (VYNE) raw stochastic average was set at 7.47%, which indicates a significant decrease from 92.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0246 in the past 14 days, which was lower than the 0.0828 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3556, while its 200-day Moving Average is $1.4886. However, in the short run, VYNE Therapeutics Inc’s stock first resistance to watch stands at $0.4274. Second resistance stands at $0.4488. The third major resistance level sits at $0.4826. If the price goes on to break the first support level at $0.3722, it is likely to go to the next support level at $0.3384. Now, if the price goes above the second support level, the third support stands at $0.3170.
VYNE Therapeutics Inc (NASDAQ: VYNE) Key Stats
There are 25,472K outstanding shares of the company, which has a market capitalization of 10.34 million. As of now, sales total 500 K while income totals -39,830 K. Its latest quarter income was 70 K while its last quarter net income were -5,760 K.
